Urinary tract infections (UTIs) are common bacterial infections that affect both pediatric and adult patients in community and hospital settings. *Escherichia coli* is the most predominant uropathogen, causing approximately 80% of uncomplicated cystitis in adult females ([@b1-idmm-26-33]--[@b3-idmm-26-33]). Treatment of acute uncomplicated cystitis typically involves oral therapy with nitrofurantoin, with alternative therapies including cefixime, trimethoprim-sulfamethoxazole (TMP-SMX), trimethoprim or ciprofloxacin ([@b4-idmm-26-33]). However, the increasing proportion of uropathogens that are resistant to recommended antibiotic treatments challenges the appropriate care and management of UTIs and limits the potential benefits of these drugs ([@b5-idmm-26-33],[@b6-idmm-26-33]).

Evidence from national surveillance programs in Canada suggests that antimicrobial resistance among uropathogens has increased in recent years ([@b7-idmm-26-33]--[@b9-idmm-26-33]). In British Columbia (BC), there has been a ninefold increase in the proportion of *E coli* isolates nonsusceptible to ciprofloxacin from 1999 to 2011, with the highest resistance rates observed among elderly age groups ([@b10-idmm-26-33]). In 2011, more than one-quarter (27%) of *E coli* isolates in BC were resistant to ciprofloxacin, more than one-quarter (26%) were resistant to TMP-SMX and almost one-half (46%) were resistant to ampicillin ([@b10-idmm-26-33]). Risk factors for developing a drug-resistant UTI include having had a previous UTI, previous antimicrobial exposure, recent hospitalization, long-term care residence, male sex, older age and comorbidities such as diabetes ([@b11-idmm-26-33]--[@b15-idmm-26-33]).

Ongoing surveillance of antimicrobial resistance trends is necessary to assess the overall burden of antimicrobial resistance over time and to derive empirical treatment guidelines for bacterial infections. However, conveying this information in an understandable and cohesive manner to policymakers and health care practitioners is challenging, particularly when resistance rates are examined separately for each drug and when trends are inconsistent across drug classes ([@b16-idmm-26-33]). Further challenges arise when these trends are interpreted in the absence of information on the proportional use of antimicrobials used to treat a given infection, or the availability and relative effectiveness of alternative treatments ([@b16-idmm-26-33]). A drug resistance index (DRI) can overcome these challenges by aggregating resistance to multiple drug classes into a single composite measure for a given bacterial species or type of infection. The purpose of the present analysis was to calculate a DRI for community UTIs caused by *E coli* in BC for the years 2007 to 2010, and to examine DRI trends over time and across patient demographics.

METHODS
=======

Data sources
------------

Antimicrobial utilization data were obtained from the BC PharmaNet database of outpatient prescriptions for oral antimicrobials for systematic use for the years 2007 to 2010. The PharmaNet database includes records of all outpatient prescriptions dispensed from community pharmacies to BC residents. It excludes over-the-counter medications, medications administered to inpatients in acute care hospitals, medication samples dispensed at a physician's office, and medications administered for veterinary or agricultural use. Antimicrobial utilization data were classified according to the WHO's Anatomical Therapeutic Chemical classification system ([@b17-idmm-26-33]).

To derive indication-specific antimicrobial utilization rates, antimicrobial prescription records were linked to diagnostic codes from the BC Medical Services Plan (MSP) files. The MSP files contain data for all medically necessary services provided by fee-for-service practitioners to BC residents covered under the provincial insurance program. Prescription records were linked to MSP records based on matching patient and physician identifiers when the prescription dispensing date occurred within five days of the practitioner service date. In instances in which more than one MSP record was extracted, the record with the most recent service date was used. Indications were defined according to the *International Classification of Diseases, Ninth Edition* (ICD-9) ([@b18-idmm-26-33]). PharmaNet-MSP linked data were restricted to ICD-9 diagnostic codes for cystitis (595) and its subcodes (595.0, 595.1, etc).

Antimicrobial resistance data for *E coli* urinary isolates were obtained from BC Biomedical Laboratories Ltd (part of LifeLabs Medical Service Laboratories as of 2013), a community-based laboratory practice serving the Vancouver Coastal and Fraser Health Authorities in BC, for the years 2007 to 2010. Testing of isolates conformed to Clinical and Laboratory Standards Institute guidelines ([@b19-idmm-26-33]).

Annual population estimates used in the calculation of antimicrobial utilization rates were obtained from the BC Health Data Warehouse ([@b20-idmm-26-33]).

Analysis
--------

Analyses were performed separately for adults ≥15 years of age and children \<15 years of age. In adults, antimicrobial utilization rates were calculated as the defined daily dose (DDD) per 1000 population per day, where DDD represents the average maintenance dose per day for a drug used in its main indication in adults ([@b17-idmm-26-33]). In children, antimicrobial utilization rates were calculated as the total number of prescriptions per 1000 population per day because antimicrobial dosing in pediatric patients varies according to weight.

An adaptive-use DRI for *E coli* was calculated according to methods adapted from Laxminarayan and Klugman ([@b16-idmm-26-33]) using the formula: $$\text{R} = \sum\limits_{\text{k}}{\text{p}_{\text{k}}^{\text{t}}\text{q}_{\text{k}}^{\text{t}}}$$where $\text{p}_{\text{k}}^{\text{t}}$ is the rate of resistance to drug class k at time t and $\text{q}_{\text{k}}^{\text{t}}$ is the proportional rate of use for drug class k used to treat cystitis at time t. Higher index values indicate more resistance.

For contrast, a 'static use' model was used to measure the hypothetical DRI trend had proportional antimicrobial use remained unchanged over time ([@b16-idmm-26-33]). Differences between static and observed adaptive DRIs help gauge the contributions of physician-adaptation to preserving the value of initial empirical therapy. The static DRI was calculated using the proportional rate of use for drug class k fixed to the baseline year of the analysis. To ensure comparability of results with those of previous studies, a sensitivity analysis was also performed using overall prescription data for any indication rather than prescription data specifically for the treatment of cystitis.

Anatomical Therapeutic Chemical drug classes were restricted to drug classes relevant to the treatment of UTIs caused by *E coli*, where data were available. These included: penicillins with extended spectrum (J01CA), first-generation cephalosporins (J01DB), third-generation cephalosporins (J01DD), fluoroquinolones (J01MA), nitrofuran derivatives (J01XE) and sulphonamide/trimethoprim combinations (J01EE). An isolate was considered to be resistant to a drug class if it was found to be nonsusceptible to at least one antimicrobial agent within that class ([@b21-idmm-26-33]). It should be noted that cefotaxime resistant cut-off ranges were modified in 2010, but that standards otherwise remained constant throughout the study period.

Stratified analyses were performed according to patient demographic characteristics (ie, age group and sex). Trends in DRIs were assessed using the nonparametric Spearman Rank test. Percentile CIs were calculated using nonparametric bootstrap methods with m=1000 simulations performed on an approximately 10% sample (PharmaNet = 47,782 observations; BC Biomedical = 13,166 observations) drawn at random from the full datasets. Ethics approval for the present analysis was obtained from the Clinical Research Ethics Board at the University of British Columbia (Vancouver, British Columbia). All analyses were performed using SAS version 9.2 (SAS Institute, USA).

RESULTS
=======

Among both patient populations, the highest resistance rates were observed for ampicillin (43.8% for adults and 46.9% for children) in the baseline year, followed by cephalothin (25.8% and 20.1%), TMPSMX (25.1% and 26.2%) and ciprofloxacin (22.7% and 7.1%). Resistance rates for cefotaxime (11.8% and 6.5%) and nitrofuratoin (3.3% and 1.3%) remained relatively low for both patient populations across all study years. For adults, resistance rates were generally stable over time despite a trend toward increasing resistance to fluoroquinolones (P\>0.05) ([Figure 1A](#f1-idmm-26-33){ref-type="fig"}). For children, resistance rates for ampicillin significantly decreased over time (rho=−1.00; P\<0.01), while resistance rates for ciprofloxacin significantly increased (rho=1.00; P\<0.01) ([Figure 1B](#f1-idmm-26-33){ref-type="fig"}). Resistance rates for all other included drug classes were stable (P\>0.05).

Among adults, fluoroquinolones comprised the largest proportional use at 37.9% in the baseline year, followed by nitrofuran derivatives (32.1%) and sulphonamide/trimethoprim combinations (21.4%) ([Figure 2A](#f2-idmm-26-33){ref-type="fig"}). Proportional use of fluoroquinolones (rho=−1.00; P\<0.01) and sulphonamide/trimethoprim combinations (rho=−1.00; P\<0.01) significantly decreased during the study period, corresponding to a significant increase in the proportional use of nitrofuran derivatives (rho=1.00; P\<0.01).

Among children, sulphonamide/trimethoprim combinations comprised the largest proportional drug use at \>50% across all study years ([Figure 2B](#f2-idmm-26-33){ref-type="fig"}). A significant decreasing trend in proportional use was observed for sulphonamide/trimethoprim combinations over time (rho=−1.00; P\<0.001), while significant increasing trends were observed for third-generation cephalosporins (rho=1.00; P\<0.001) and nitrofuran derivatives (rho=1.00; P\<0.001).

Among adults, the adaptive-use DRI, when averaged across all study years, was 0.18 (95% CI 0.17 to 0.18) and remained stable over time (rho=−0.80; P=0.20) ([Figure 3A](#f3-idmm-26-33){ref-type="fig"}). The static-use DRI increased from 0.18 (95% CI 0.17 to 0.19) in 2007 to 0.20 (95% CI 0.19 to 0.21) in 2010; however, the overall trend was not significant (rho=0.80; P=0.20). DRI values for the static-use model did not significantly differ from the adaptive-use model over the four years of study, as indicated by the overlapping 95% CIs. DRI values did not dramatically differ when total number of prescriptions (versus DDDs) was used to calculate proportional antimicrobial use for adults (data not shown).

Among children, the adaptive-use DRI peaked at 0.30 (95% CI 0.25 to 0.35) in 2008 then declined to 0.27 (95% CI 0.22 to 0.32) in 2010; however, this trend was not significant (rho=−0.40; P=0.60) ([Figure 3B](#f3-idmm-26-33){ref-type="fig"}). Nearly identical DRI values were observed for the static-use model.

Fluoroquinolones and sulphonamide/trimethoprim combinations made the largest contribution to the DRI among adults across all years, while among children the trend in DRI values was predominantly driven by sulphonamide/trimethoprim combinations and penicillins with extended spectrum ([Table 1](#t1-idmm-26-33){ref-type="table"}). Other drug classes had relatively less impact on DRI trends among both adults and children. Analyses according to age group and sex show that DRI values were consistently higher among males than females across all age groups ([Figure 4](#f4-idmm-26-33){ref-type="fig"}). For adults, there was a significant increasing trend from 0.09 (95% CI 0.08 to 0.11) among those 15 to 19 years of age to 0.32 (95% CI 0.29 to 0.34) among those \>90 years of age (rho=0.95; P\<0.01). For children, there was a significant declining trend from 0.35 (95% CI 0.27 to 0.43) among those \<1 year of age to 0.17 (95% CI 0.13 to 0.22) among those 10 to 14 years of age (rho=−1.00; P\<0.01).

Sensitivity analysis
--------------------

A sensitivity analysis was performed using overall, rather than indication-specific, prescription data to calculate proportional drug use. Among both patient populations, penicillins with extended spectrum were the most frequently used antimicrobial class for any indication in the baseline year (43.4% for adults and 75.0% for children), followed by fluoroquinolones (22.1% and 0.4%, respectively), first-generation cephalosporins (14.8% and 12.4%, respectively), sulphonamide/trimethprim combinations (11.5% and 9.6%, respectively), nitrofuran derivatives (7.5% and 0.4%, respectively) and third-generation cephalosporins (0.7% and 2.2%, respectively). Among adults, the adaptive-use DRI was significantly higher at 0.31 (95% CI 0.31 to 0.32) when overall prescription data were used. The adaptive-use DRI remained stable over time (rho=0.40; P=0.60) and did not significantly differ from the static-use model. Among children, the adaptive-use DRI was significantly higher at approximately 0.40 (95% CI 0.37 to 0.43) when overall prescription data were used and remained stable over time (rho=−0.80; P=0.20).

DISCUSSION
==========

The DRI reflects the proportion of prescriptions for *E coli* cystitis in a population that uses a drug to which the organism is not susceptible. Our findings show that the overall DRI value for community *E coli* urinary isolates, when averaged across study years, is 18% (95% CI 17% to 18%) among adults ≥15 years of age. This value is lower than the *E coli* DRI of 30% (95% CI 29% to 32%) reported by Laxminarayan and Klugman ([@b16-idmm-26-33]) for 2006, likely because our study used indication-specific antimicrobial utilization data, which will more accurately reflect the tailored selection of antimicrobials for the treatment of UTIs. Sensitivity analyses based on overall prescribing for any indication found DRI values more consistent with previously reported values at 31% (95% CI 31% to 32%), largely driven by the greater proportional use of extended-spectrum penicillins. Our analyses were stratified according to age group, which may also partially explain the discrepancy with previous findings. While resistance rates were similar between adults ≥15 years of age and children \<15 years of age, the higher proportional use of extended-spectrum pencillins and sulphonamide/trimethoprim combinations among children increased the relative contribution of these drug classes to the age-specific DRI. For children, the overall DRI value across all study years was 28% (95% CI 26% to 31%). Geographical variability may also be a factor because resistance rates are known to be significantly higher in the United States in comparison with Canada ([@b8-idmm-26-33],[@b9-idmm-26-33]).

Adaptive-use DRI trends remained stable over time, and DRI values based on a static-use model that fixes proportional antimicrobial use to the baseline year did not significantly differ from an adaptive-use model. However, even over this short study period, the static index appears to be trending upward. A contrast between the value of the observed adaptive and static DRI is consistent with physicians increasing the proportionate use of nitrofurantoin. Physicians appear to have been increasing their use of this drug at the expense of TMP-SMX and ciprofloxacin. This change could be in response to evolving guidelines, emphasis in continuing education sessions or individual physician attention to antibiograms. Whatever the driver, physicians may be adapting prescribing practices to local resistance patterns ([@b16-idmm-26-33]). However, the limited availability of data makes it difficult to assess long-term trends. Others have noted rising resistance rates over time associated with the clonal spread of virulent, multidrug-resistant strains ([@b7-idmm-26-33],[@b22-idmm-26-33]), including extended-spectrum beta-lactamase-producing strains of community-acquired *E coli* ([@b23-idmm-26-33],[@b24-idmm-26-33]). A longer duration of surveillance will be required to monitor the impact of extended-spectrum beta-lactamase-producing *E coli* strains on DRI trends in BC.

Consistent with recent guidelines ([@b4-idmm-26-33],[@b25-idmm-26-33]), our data suggest that nitrofurantoin is an appropriate treatment for acute uncomplicated cystitis given its low observed resistance rates. While this may be good news for cystitis, nitrofurantoin is not indicated for the treatment of pyelonephritis due to inadequate concentrations achieved in renal tissues and should not be used if early pyelonephritis is suspected ([@b4-idmm-26-33],[@b25-idmm-26-33]). Despite earlier research suggesting that nitrofurantoin has lower clinical cure rates and more side effects than traditional first-line agents, namely TMP-SMX and fluoroquinolones ([@b26-idmm-26-33]), more recent studies suggest that empirical treatment with nitrofurantoin is as effective as these drugs ([@b25-idmm-26-33]). Given the concerning resistance trends observed for ciprofloxacin and TMP-SMX, our findings support calls made by others for more judicious use of these drugs ([@b8-idmm-26-33],[@b25-idmm-26-33]--[@b27-idmm-26-33]). Routine testing data were not available for our study period for other, alternative treatments for UTIs, such as fosfomycin, which has only recently become available again in Canada.

DRI trends according to age group suggest a U-shaped distribution with the lowest rates occurring among adults \<50 years of age and the highest rates occurring among young children and the elderly. Elderly adults are at greater risk for developing a drug-resistant infection, likely as a result of cumulative lifetime exposure to antimicrobials, particularly to fluoroquinolones, higher frequency and longer duration of hospital stays, increased likelihood of developing complicated infections and increased prevalence of comorbidities ([@b7-idmm-26-33],[@b11-idmm-26-33],[@b12-idmm-26-33],[@b14-idmm-26-33]). While acute, uncomplicated UTIs are generally self-limiting and not associated with long-term medical sequelae in adults in the absence of underlying conditions ([@b1-idmm-26-33],[@b28-idmm-26-33]), among pediatric patients, UTIs can be associated with significant morbidity, including impaired renal function and end-stage renal disease ([@b28-idmm-26-33],[@b29-idmm-26-33]).

Males had consistently higher DRI values than females across all age groups, a finding that is consistent with resistance trends observed nationally ([@b7-idmm-26-33]--[@b9-idmm-26-33]). These trends are largely driven by the greater proportional use of fluoroquinolones for cystitis and the higher rates of ciprofloxacin resistance among men (data not shown). The high prevalence of complicated UTIs among men, combined with the longer duration of therapies and older age at diagnosis, likely explains the higher observed resistance rates ([@b7-idmm-26-33],[@b30-idmm-26-33],[@b31-idmm-26-33]). In children, this sex difference is likely the result of congenital abnormalities, which are more prevalent among males than females ([@b29-idmm-26-33],[@b30-idmm-26-33]).

The present study extends previous work in this area in a number of important ways. Access to prescription drug use through BC PharmaNet allows for examination of antimicrobial utilization in community settings for the entire population of BC. We have adopted standardized methods of measuring antimicrobial use in units of DDDs ([@b17-idmm-26-33]) and established linkage methodologies to connect antimicrobial prescriptions to ICD-9 diagnostic codes to derive indication-specific antimicrobial prescribing ([@b32-idmm-26-33],[@b33-idmm-26-33]). However, despite these strengths, certain limitations should be acknowledged. Prescription data from PharmaNet are restricted to oral antimicrobials dispensed in out-patient settings. While these data comprehensively measure prescription use in the community -- the main focus of our study -- they do not capture antimicrobial use for agents that are administered parenterally and/or primarily used in inpatient settings. As a result, utilization rates for certain drug classes may be underestimated in our study or, in the case of carbapenems and aminoglycosides, excluded completely. The accuracy of data on indication-specific prescribing will depend on the manner in which physicians code the diagnosis when billing. We focused on the majority of UTIs for which a cystitis code (ICD-9 595) was coded to assure specificity of that diagnosis in describing treatment patterns, UTIs identified by less specific codes (eg, ICD-9 599) were excluded. Nonetheless, our linked data analysis reflects patterns of prescription for an entire population. BC Biomedical Laboratories are located in only two of five of the regional health authorities in BC, and, although one of the largest laboratory service providers in BC, they are not the sole provider of outpatient laboratory services in these areas. However, we have observed only limited variation in prescribing by region in BC. Future analyses will begin with more complete sampling of laboratory data through collaboration with broader laboratory systems.

Routine susceptibility testing of penicillins with beta-lactamase inhibitors (eg, amoxicillin-clavulanate) was only performed from 2009 onwards; consequently, this antimicrobial class was excluded from our analysis to ensure comparability of DRI values over time. Culture samples are generally not indicated for young, otherwise healthy, premenopausal women. As such, isolates may be more representative of certain patient populations with higher resistance rates such as those with complicated UTIs ([@b7-idmm-26-33]--[@b9-idmm-26-33]). Finally, DRIs for adults and children in the present analysis may not be directly comparable due to differences in their calculations (refer to the Methods section).

CONCLUSIONS
===========

DRIs improve our ability to quantify and communicate the cumulative impact of antimicrobial resistance on the likelihood that an organism will be susceptible to initial antimicrobial treatment. For clinicians, they provide information on the effectiveness of alternative treatment regimens and the relative adaptability of these treatments to local resistance patterns. For policymakers and other nonexpert groups, DRIs function as an important communication tool for translating knowledge about antimicrobial resistance into practice. Our findings show that the overall DRI value for community UTIs caused by *E coli* in BC is 18% for adults and 28% for children for the years 2007 to 2010. The likelihood that a UTI caused by *E coli* will be susceptible to initial antimicrobial therapy is highest among adult females, while concerning DRI values were observed among young children and the elderly. Further work is required to develop a DRI to summarize the impact of resistance on all relevant pathogens causing UTI in a population.
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###### 

Resistance rates for *Escherichia coli* urinary isolates and proportional rates of antimicrobial use for cystitis among adults ≥15 years of age and children \<15 years of age in British Columbia, 2007--2010

  **Drug class (antibiotic)**                         **Resistance rate (A), %**   **Proportional antimicrobial use (B), %**   **Drug resistance index (A\*B)**   **95% CI for drug resistance index**
  --------------------------------------------------- ---------------------------- ------------------------------------------- ---------------------------------- --------------------------------------
  Adults                                                                                                                                                          
    Penicillins with extended spectrum (ampicillin)   44.3                         5.5                                         0.02                               
    First-generation cephalosporins (cephalothin)     24.3                         2.4                                         0.01                               
    Third-generation cephalosporins (cefotaxime)      10.6                         0.9                                         0.00                               
    Sulfonamides and trimethoprim (TMP-SMX)           25.8                         19.1                                        0.05                               
    Fluoroquinolones (ciprofloxacin)                  24.7                         35.3                                        0.09                               
    Nitrofuran derivatives (nitrofurantoin)           3.8                          36.7                                        0.01                               
  Sum                                                                                                                          0.18                               0.17--0.18
  Children                                                                                                                                                        
    Penicillins with extended spectrum (ampicillin)   45.8                         23.9                                        0.11                               
    First-generation cephalosporins (cephalothin)     19.3                         9.1                                         0.02                               
    Third-generation cephalosporins (cefotaxime)      6.2                          4.4                                         0.00                               
    Sulfonamides and trimethoprim (TMP-SMX)           27.1                         55.6                                        0.15                               
    Fluoroquinolones (ciprofloxacin)                  9.2                          1.6                                         0.00                               
    Nitrofuran derivatives (nitrofurantoin)           2.0                          5.4                                         0.00                               
  Sum                                                                                                                          0.28                               0.26--0.31

TMP-SMX Trimethoprim-sulfamethoxazole
